ReviewBioMed research international2021
Ectoine in the Treatment of Irritations and Inflammations of the Eye Surface.
Review in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Ectoine Inhibits IL-1β-Induced Inflammation by Suppressing the NF-κB Pathway in Chondrocytes and Alleviates Osteoarthritis in a Rat Model.Biomedicines · 2026Article
- Complete Genome Sequencing of Streptomyces sp. Qhu-M197 Isolated from Alpine Meadows in the Qinghai-Tibetan Plateau Uncovers Biosynthetic Gene Clusters Encoding Bioactive Natural Products.Biochemical genetics · 2026Article
- Extremophile-Derived Bioactives in Cosmeceuticals: Bridging Nutraceuticals and Skincare for Holistic Wellness.Life (Basel, Switzerland) · 2025Review
- Article
- Continuous Valorization of Carbon Dioxide into the Fine Chemical Ectoine byEnvironmental science & technology · 2025Article
- Ophthalmic Formulations for the Treatment of Allergic Conjunctivitis and Their Effect on the Ocular Surface: A Review of Safety and Tolerability Assessments in Clinical Trials.Journal of clinical medicine · 2024Review
- Determination of the extremolyte ectoine in plasma and a pharmacokinetic study in rats by a validated and BAGI-evaluated UPLC-MS/MS method.BMC chemistry · 2024Article
- Analyze interleukin-1β, interleukin-6, and tumor necrosis factor-α levels in dry eye and the therapeutic effect of cyclosporine A.World journal of clinical cases · 2024Article
- Ectoine Enhances Mucin Production Via Restoring IL-13/IFN-γ Balance in a Murine Dry Eye Model.Investigative ophthalmology & visual science · 2024Article
- Rational engineering of Halomonas salifodinae to enhance hydroxyectoine production under lower-salt conditions.Applied microbiology and biotechnology · 2024Article
- Ectoine, from a Natural Bacteria Protectant to a New Treatment of Dry Eye Disease.Pharmaceutics · 2024Article
- Dry Eye Disease in the Middle East and Northern Africa: A Position Paper on the Current State and Unmet Needs.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Protective effects of ectoine on articular chondrocytes and cartilage in rats for treating osteoarthritis.PloS one · 2024Article
- Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Ectoine Globally Hypomethylates DNA in Skin Cells and Suppresses Cancer Proliferation.Marine drugs · 2023Article
- Metabolomic Profiling of Aqueous Humor from Pathological Myopia Patients with Choroidal Neovascularization.Metabolites · 2023Article
- Article
- Improved salt tolerance ofFrontiers in microbiology · 2023Article
- Three novel marine species of the genusFrontiers in microbiology · 2023Article
- Bioactivity profiling of the extremolyte ectoine as a promising protectant and its heterologous production.3 Biotech · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ocular surface is facing various unspecific stress factors resulting in irritation and inflammation of the epithelia, causing discomfort to the patients. Ectoine is a bacteria-derived extremolyte with the ability to protect proteins and biological membranes from damage caused by extreme environmental conditions like heat, UV-light, high osmolarity, or dryness. Evidence from preclinical and clinical studies attest its effectiveness in treating several epithelium-associated inflammatory diseases, including the eye surface. In this review, we analysed 16 recent clinical trials investigating ectoine eye drops in patients with allergic conjunctivitis or with other unspecific ocular inflammations caused by e.g. ophthalmic surgery. Findings from these studies were reviewed in context with other published work on ectoine. In summary, patients with irritations and unspecific inflammations of the ocular surface have been treated successfully with ectoine-containing eye drops. In these patients, significant improvement was observed in ocular symptoms of allergic rhinoconjunctivitis, postoperative secondary dry eye syndrome, or ocular reepithelisation after surgery. Using ectoine as an add-on therapy to antihistamines, in allergy patients accelerated symptom relief by days, and its use as an add-on to antibiotics resulted in faster wound closure. Ectoine is a natural substance with an excellent tolerability and safety profile thus representing a helpful alternative for patients with inflammatory irritation of the ocular surface, who wish to avoid local reactions and side effects associated with pharmacological therapies or wish to increase the efficacy of standard treatment regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.